Genmab — December 2025

[Helge_LarsenPI-redaktør]

Godmorgen

[E_L]

Bispecifics Are Shifting the Treatment Paradigm in Follicular Lymphoma: Highlights From ASH 2025 https://www.oncologynewscentral.com/video/lymphoma/bispecifics-are-shifting-the-treatment-paradigm-in-follicular-lymphoma-highlights-from-ash-2025

[E_L]

(you can click on 'transcript' if you find it easier to read instead of listen)

[gentogen]

Hvis nogen vidste noget, ville det vel have
giver mere mening at købe op I Merus,

[gentogen]

Kan vel også tænkes, at "markedet" gerne vi se fase 3 data af petosemtamab, før det for alvor tilskrives kommende meget stor værdi

[lahn1]

Jeg er vild med traditioner men i denne traditionsbundne tid er der særligt en jeg savner @Helge’s liste med Nytårs raketter får vi mon sådan en i år ?

[JKY_VH]

God ide lahn1, den må vi have:-)

[Helge_LarsenPI-redaktør]

lahn....Den slags var på foranledning af Mioklubben. Her stoppede jeg vist traditionen i 2015.

[lahn1]

Som vores åndelige leder, er det jo en enestående chance for at lede dine discipler på rette vej men fair nok den var ellers en sjov liste til inspiration.

[transalp]

enig lahn1...

[nohope]

Hvis man trænger til lidt underholdning, så er der jo altid Saxos vilde forudsigelser.https://www.home.saxo/da-dk/insights/news-and-research/thought-leadership/outrageous-predictions

[nohope]

Deres succesrate er lavere end gift ved første blik.....

[nohope]

Men underholdningsværdien er ok.

[E_L]

FDA Proactively Awards National Priority Voucher Based on Strong Phase 3 Study Results

For Immediate Release:
December 15, 2025

The U.S. Food and Drug Administration today awarded a national priority voucher to teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma. https://www.fda.gov/news-events/press-announcements/fda-proactively-awards-national-priority-voucher-based-strong-phase-3-study-results

[E_L]

"Argenx cans thyroid eye disease trials of Vyvgart Hytrulo" ; was a future potential competitor for Tepezza

[lahn1]

Det sku vel aldrig være der deres pille skal produceres ?

[E_L]

Cami still manages an article in Blood... Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study https://ashpublications.org/bloodadvances/article/9/23/6205/546723/Camidanlumab-tesirine-for-relapsed-or-refractory

[gentogen]

Thanks again EL: Quote: "Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile"

[E_L]

small new trial - Phase I/​II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT07283679

[Helge_LarsenPI-redaktør]

Genmab får løftet kursmålet til 2900 kr. hos Kempen https://proinvestor.com/investornyt/1394515/genmab-far-loftet-kursmalet-til-2900-kr-hos-kempen